SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that a study indicating that noninvasive prenatal genetic testing using maternal plasma may be routinely used to characterize fetal Rhesus D (RHD) genotypes was presented in a poster session at the American College of Obstetricians and Gynecologists (ACOG) 56th Annual Clinical Meeting being held in New Orleans. The “blue ribbon” designation is reserved for those abstracts receiving the highest ranking by ACOG.
